Publications by authors named "J Vives i Batlle"
Study Objectives: Actigraphy devices are used in sleep medicine. The Actiwatch 2 (Philips Respironics) was an example of a frequently used device in this field. Nevertheless, the discontinuation of this device has led to an increased necessity for the implementation of other available actigraphy methods capable of providing objective information.
View Article and Find Full Text PDFPurpose: To report the 12-month clinical outcomes in eyes with mild to moderate open-angle glaucoma (OAG) in Hispanic adults undergoing STREAMLINE Surgical System (STREAMLINE) canaloplasty combined with phacoemulsification.
Patients And Methods: This was a prospective, multi-center, interventional clinical trial involving 45 eyes of 45 Hispanic adult patients receiving topical medical therapy for mild to moderate OAG and undergoing phacoemulsification surgery for visually significant cataracts at three sites. All eyes underwent a Screening visit, followed by medication washout and a subsequent Baseline visit to determine eligibility for STREAMLINE canaloplasty.
Article Synopsis
- Obstructive sleep apnea (OSA) significantly impacts cardiovascular event recurrence in patients with acute coronary syndrome (ACS), particularly in those without prior cardiovascular disease.
- The study identified two groups based on the severity of OSA and utilized proteomics to analyze plasma proteins, revealing 24 differentially expressed proteins associated with OSA severity.
- Bioinformatic analysis suggested that these proteins are involved in key molecular pathways related to immune function, cell signaling, and inflammation, linking OSA to adverse cardiovascular outcomes.
Introduction: Randomized controlled trials (RCT) have not demonstrated a role for continuous positive airway pressure (CPAP) on the secondary prevention of major cardiovascular events in obstructive sleep apnea (OSA) patients. However, participants in RCTs are substantially different from real-world patients. Therefore, we aimed to assess the effect of CPAP treatment on major cardiovascular events in real-world OSA patients.
View Article and Find Full Text PDFCombining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study.
Lancet Oncol
July 2024
Article Synopsis
- Current treatments for metastatic pancreatic ductal adenocarcinoma yield very low survival rates, prompting research into new therapies like mitazalimab combined with a modified chemotherapy regimen called mFOLFIRINOX.
- The OPTIMIZE-1 study enrolled 70 patients across 14 hospitals in Belgium, France, and Spain to evaluate the safety and effectiveness of this combination therapy, focusing on determining the optimal dose of mitazalimab as well as measuring tumor response.
- The trial successfully determined 900 μg/kg of mitazalimab as the recommended dose for the next phase and gathered data on the initial outcomes for the patients treated within the study timeframe from September 2021 to March 2023.